Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: Forty-four patients were eligible for this analysis. The proportion of patients, who experienced at least one episode of grade ≥ 1 acute vomiting in patients receiving SSRI, compared to patients who did not, was significantly higher (59.1 vs. 22.7%, respectively, p = 0.03, odds ratio 4.72, 95% confidence interval 1.13-22.88). Grade ≥ 2 acute vomiting was also significantly more frequent in patients receiving SSRI, even after the implementation of aprepitant to antiemetic prophylaxis (41.2 vs. 5.9%, p = 0.04). CONCLUSIONS:
|
Authors | Olivier Mir, Jean-Philippe Durand, Pascaline Boudou-Rouquette, Julie Giroux, Romain Coriat, Anatole Cessot, Stanislas Ropert, François Goldwasser, Raphaël Gaillard |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 20
Issue 9
Pg. 2235-9
(Sep 2012)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 22644261
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antiemetics
- Antineoplastic Agents, Phytogenic
- Morpholines
- Serotonin Antagonists
- Serotonin Uptake Inhibitors
- Aprepitant
- Platinum
- Etoposide
|
Topics |
- Adult
- Aged
- Antiemetics
(therapeutic use)
- Antineoplastic Agents, Phytogenic
(adverse effects, therapeutic use)
- Aprepitant
- Case-Control Studies
- Drug Interactions
- Drug Therapy, Combination
(adverse effects, methods)
- Etoposide
(adverse effects)
- Female
- Humans
- Male
- Middle Aged
- Morpholines
(pharmacology)
- Nausea
(chemically induced, drug therapy)
- Neoplasms
(drug therapy)
- Platinum
(adverse effects)
- Serotonin Antagonists
(pharmacology)
- Selective Serotonin Reuptake Inhibitors
(pharmacology)
- Vomiting
(chemically induced, drug therapy)
|